Clinical Trials

87 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT06281405 2026-04-03

TORCH-iTNT

192 enrolled

Locally Advanced Rectal Cancer

NCT06706219 2026-04-03

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

50 enrolled

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07500831 2026-03-30

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

43 enrolled

Carcinoma, Renal Cell

NCT07493980 2026-03-27

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07480733 2026-03-25

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Phase 1 Active not recruiting

480 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumors

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Dermatologic

Skin Neoplasms

NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Phase 1/2 Not yet recruiting

52 enrolled

Nasopharyngeal Carcinoma

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Phase 3 Recruiting

298 enrolled

Carcinoma, Renal Cell

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

146 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT05798845 2026-03-11

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

124 enrolled

Phase 1 Active not recruiting

NSCLC

NCT04651127 2026-03-10

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Phase 1/2 Terminated

5 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05707910 2026-03-09

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

6 enrolled

Tumor-Agnostic

Neoplasms

NCT07209189 2026-03-09

(NeoScorch HN)

75 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT07457359 2026-03-09

NEOTRIO-2

18 enrolled

Triple Negative Breast Neoplasms

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Carcinoma, Renal Cell

NCT06208826 2026-03-03

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

268 enrolled

Head and Neck Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Phase 1/2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07277322 2026-03-02

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Colorectal Neoplasms

NCT05888402 2026-02-27

InTRist

50 enrolled

Local Advanced Non-small Cell Lung Cancer

NCT07281716 2026-02-19

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Phase 1/2 Recruiting

Colorectal Neoplasms

NCT07410234 2026-02-13

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

110 enrolled

Breast Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

Nasopharyngeal Carcinoma

NCT07290621 2026-02-06

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

30 enrolled

Oropharyngeal Neoplasms

NCT04418648 2026-02-04

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Phase 2 Terminated

170 enrolled

Small Cell Lung Cancer Limited Stage

NCT07383818 2026-02-03

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

111 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06952621 2026-01-30

TD-NEOE3V3

390 enrolled

Esophageal Squamous Cell Carcinoma

NCT07378306 2026-01-30

FACT-TN

80 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07371897 2026-01-28

SHINE

154 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07363330 2026-01-26

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer

32 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT07358689 2026-01-22

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

120 enrolled

NSCLC

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

10 enrolled

Pathologic Complete Response, Head and Neck Neoplasms

NCT07342322 2026-01-15

A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

25 enrolled

Sarcoma

NCT06682195 2026-01-14

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

35 enrolled

Triple Negative Breast Neoplasms

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Phase 3 Recruiting

300 enrolled

Phase 1 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06283134 2026-01-07

A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

60 enrolled

Colorectal Neoplasms

NCT06416696 2026-01-02

Toripalimab for High-risk Locally Advanced Cervical Cancer

57 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07309276 2025-12-30

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

864 enrolled

Advanced Lung Cancer

NCT07308379 2025-12-29

Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer

Not yet recruiting

1,200 enrolled

SCLC, Extensive Stage

NCT06584435 2025-12-19

TUORA

100 enrolled

High-risk Renal Cell Carcinoma

NCT07279597 2025-12-19

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

45 enrolled

Muscle-invasive Bladder Urothelial Carcinoma

NCT06293690 2025-12-18

Toripalimab Combined With SBRT for NSCLC

40 enrolled

Non-small Lung Cancer

NCT07286942 2025-12-16

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

Carcinoma, Non-Small-Cell Lung

NCT07272291 2025-12-09

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

48 enrolled

GastrointestinalGynecologic

Esophageal Squamous Cell Carcinoma

NCT05427396 2025-12-03

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Phase 1 Terminated

31 enrolled

Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms, Liver Neoplasms

NCT06735131 2025-12-03

The Optimal Radioimmunotherapy Combinations for Advanced TNBC

60 enrolled

Triple Negative Breast Neoplasms

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Phase 1/2 Completed

119 enrolled